HASBROUCK HEIGHTS, N.J., Aug. 22, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported favorable results from the most recent Safety Monitoring Committee periodic review of safety data for the Company's NX02-0018 clinical trial, one of the two Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The August 20, 2013 Safety Monitoring Committee meeting found no significant safety concerns to date. Both of the Company's pivotal Phase 3 trials have completed enrollment and treatment (a single intraprostatic injection of either drug or placebo) and patient evaluation is continuing at over 70 well-known urology investigative sites across the U.S. NX-1207 for the treatment of BPH is in Phase 3 development in the U.S. and in the EU under the sponsor of the Company's European licensing partner, Recordati S.p.A. NX-1207 is a first-in-class therapeutic that is administered directly into the prostate by a urologist in an office setting. The procedure does not require anaesthesia, sedation, or catheterization, takes only a few minutes and involves minimal discomfort to the patient. NX-1207 has thus far shown none of the adverse sexual side effects associated with approved medical and surgical treatments for BPH. Previous clinical trials found that a single administration of NX-1207 2.5 mg produced on average improvements in the standardized BPH symptom score (8-10 points at 90 days) that were approximately double that reported for currently approved BPH drugs (3-5 points) without the sexual, blood pressure, or other side effects associated with the approved drugs. Follow-up studies have shown durable clinically significant benefit for up to 7 ½ years after a single treatment. BPH is one of the most commonly diagnosed diseases in older men. The condition can have a significant negative impact on a man's health and quality of life and can lead to acute urinary retention, incontinence and other serious consequences. It is estimated that 50% of men in their 50s have pathological signs of prostatic hyperplasia and from 26 to 46% of men between the ages of 40 to 79 years suffer from moderate to severe urinary problems and symptoms associated with BPH.
CONTACT: For Further Information Contact: Brian Doyle Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com